Asbestosis Treatment Market Size, Forecast, Demand, 2034
| Company | Value (USD) | Details |
|---|---|---|
| Celea Therapeutics | USD 180 Million | In July 2026, Celea Therapeutics announced financing to advance Phase 3 development of deupirfenidone for idiopathic pulmonary fibrosis. |
| University of Iowa | USD 2.55 Million | In August 2025, the University of Iowa announced NIH funding for the development of a portable oxygen concentrator using electrochemical technology. |
Long Disease Latency and Need for Long-Term Respiratory Support Drive Market
The long latency period of asbestosis is sustaining demand for respiratory treatment among previously exposed workers. Symptoms often develop 20–40 years after asbestos exposure, creating treatment needs decades after occupational contact. The World Health Organization estimates that occupational asbestos exposure causes more than 200,000 deaths globally each year across asbestos related diseases. The continuing disease burden supports demand for oxygen therapy and long-term pulmonary care.
The progressive nature of asbestosis increases dependence on continuous medical care as lung function deteriorates. Patients with advanced disease may require supplemental oxygen to manage breathing difficulties. Regular pulmonary function assessments and respiratory monitoring also remain essential throughout treatment. The absence of curative treatment creates sustained demand for supportive care services and oxygen delivery equipment, particularly among patients experiencing severe respiratory impairment.
Market RestraintsAbsence of Curative Therapies and Limited Access to Specialized Pulmonary Rehabilitation Restrain Market Expansion
The absence of disease-reversing treatment remains a major restraint in the asbestosis treatment market. Existing therapies primarily manage breathing difficulties without removing established lung scarring. Oxygen therapy and pulmonary rehabilitation provide supportive benefits but cannot reverse asbestos-related fibrosis.
The limited availability of specialized pulmonary rehabilitation services restricts treatment access for asbestosis patients. Rehabilitation requires trained respiratory professionals and structured exercise supervision, which can be difficult to access outside major healthcare centers. Repeated hospital visits also create challenges for patients with reduced mobility.
Market OpportunitiesAI-Assisted Lung Imaging and Development of Targeted Anti-Fibrotic Therapies Creates Growth Opportunities
Integration of artificial intelligence into lung imaging presents growth opportunities for the asbestosis treatment market. AI-assisted CT analysis helps identify asbestos-related lung fibrosis and supports accurate disease assessment. These capabilities create opportunities for diagnostic technology providers and specialized pulmonary care centers.
Development of targeted anti-fibrotic therapies presents opportunities for the asbestosis treatment market. Research into macrophage activity and cellular stress mechanisms could support treatments that slow asbestos-induced lung fibrosis. The U.S. National Institutes of Health is funding research into endoplasmic reticulum stress and its role in asbestos-related disease progression through May 2029. These developments create opportunities for disease-specific drug research, although effective targeted therapies remain investigational.
Asbestosis Treatment Market Segmentation Analysis By Treatment TypeSymptomatic medication dominated the treatment type segment with a share of 34.60% in 2025 due to recurring prescriptions for cough relief and management of accompanying airway obstruction.
The pulmonary rehabilitation segment is estimated to register a growth rate of 6.70% during the forecast period, driven by the demand for supervised breathing exercises and physical conditioning. Structured rehabilitation programs improve exercise tolerance and help patients manage breathlessness.
Request Customization to receive a tailored report.
By Disease SeverityIn 2025, the moderate segment accounted for a share of 43.50% in 2025, owing to increasing treatment requirements among patients experiencing exertional breathlessness and measurable lung function decline. Regular pulmonary assessments and symptom management support continued healthcare utilization in this segment.
The severe segment will expand to 6.20% CAGR during the forecast period, as advanced pulmonary fibrosis increases dependence on supplemental oxygen. Greater risks of respiratory failure and pulmonary hypertension also increase demand for intensive respiratory care services.
By Age GroupThe adults segment is estimated to reach 5.40% CAGR during the forecast period, driven by occupational asbestos exposure among construction and industrial workers.
Geriatric population segment is projected to reach at a CAGR of 6.10% during the forecast period, as prolonged disease latency increases diagnoses in older individuals. Age-related respiratory limitations and existing cardiopulmonary conditions increase the need for specialized treatment.
By Healthcare SettingHospitals led the healthcare setting segment with a share of 46.30% in 2025, owing to the availability of specialized pulmonologists and advanced respiratory treatment facilities. Hospital-based management of acute respiratory complications and severe hypoxemia supports higher utilization of inpatient care services.
The home care settings segment is likely to witness a CAGR of 6.80% during the forecast period, supported by the use of prescribed long-term oxygen therapy and preference for portable oxygen concentrators among caregivers.
Speak to an Analyst to discuss market opportunities.
Asbestosis Treatment Market Regional Outlook North America Asbestosis Treatment MarketThe North America asbestosis treatment market accounted for the largest regional share of 42.10% in 2025.
U.S. Asbestosis Treatment Market
The U.S. market is supported by continued diagnosis among people exposed to asbestos decades earlier and by persistent exposure risks in older buildings. EPA identifies legacy asbestos in buildings as a continuing health concern, especially during renovation and demolition. Medicare coverage for medically necessary home oxygen equipment also supports long-term respiratory management for eligible patients with reduced oxygen levels and chronic breathing impairment.
Canada Asbestosis Treatment Market
Health Canada states that asbestos may still remain in older buildings despite restrictions on new asbestos-containing products. Continued exposure risk during renovation and maintenance supports occupational monitoring, while established respiratory care services sustain treatment needs for patients who develop progressive breathing difficulty from past exposure.
Unlock Regional Insights to access country-level data, & regional trends.
Asia Pacific Asbestosis Treatment MarketThe Asia Pacific asbestosis treatment market is expected to grow at a CAGR of 6.20% during the forecast period, showcasing the fastest-growing regional market.
China Asbestosis Treatment Market
National Health Commission reports that 900 pneumoconiosis rehabilitation stations have provided more than two million free rehabilitation visits. National respiratory disease policy also promotes pulmonary function assessment, exercise rehabilitation, and community-based management, strengthening access to supportive care for patients with chronic dust-related respiratory disease.
India Asbestosis Treatment Market
India is shaped by occupational health surveillance in asbestos product industries and access to specialized respiratory testing. DGFASLI's Industrial Medicine Division conducts health surveys in asbestos manufacturing and maintains facilities for ILO radiography and pulmonary function testing. These services can improve identification of occupational lung damage, while clinical follow-up and respiratory support remain important for workers with irreversible fibrosis and breathing impairment.
Japan Asbestosis Treatment Market
Japan's market is propelled by a national asbestos health damage relief system that covers severe asbestosis with respiratory dysfunction. Certified patients can receive medical expense support and monthly medical care allowances, reducing the financial burden of prolonged treatment. Japan also maintains formal application and medical assessment pathways for asbestos-related disease, supporting continued identification and care of patients affected by historical occupational and environmental exposure.
Europe Asbestosis Treatment MarketThe Europe asbestosis treatment market is expected to experience a growth rate of 5.10% during the forecast period.
UK Asbestosis Treatment Market
UK has an established occupational disease surveillance framework that helps identify affected workers and supports clinical follow-up. Access to respiratory specialists, pulmonary rehabilitation, oxygen therapy, and long-term symptom management continues to sustain treatment demand among patients with progressive asbestos-related lung fibrosis.
Germany Asbestosis Treatment Market
Statutory accident insurance provides a structured pathway for diagnosis, medical care, and rehabilitation of affected workers. Germany's established pulmonary care infrastructure also supports long-term disease management, while the extended latency of asbestos-related lung damage continues to generate treatment needs among previously exposed industrial and construction workers.
Latin America Asbestosis Treatment MarketThe Latin America asbestosis treatment market is anticipated to record a growth rate of 5.90% during the forecast period. Brazil's RENAST network provides specialized worker-health services through CEREST centers, supporting diagnosis, treatment, and rehabilitation for occupational diseases across a broad municipal network.
Mexico Asbestosis Treatment MarketMexico maintains specific medical surveillance requirements for asbestos-exposed workers. The national standard requires annual health examinations and includes chest radiography and spirometry, helping identify respiratory impairment and supporting continued clinical management of affected workers.
Middle East & Africa Asbestosis Treatment MarketThe Middle East & Africa asbestosis treatment market is estimated to grow at a CAGR of 6.20% during the forecast period. The UAE maintains specific asbestos handling requirements through Dubai Municipality and formal standards for occupational health services, supporting exposure assessment and referral of workers requiring respiratory evaluation.
South Africa Asbestosis Treatment MarketSouth Africa provides structured medical support for occupational lung diseases through the Compensation Commissioner for Occupational Diseases. Eligible mineworkers can receive free benefit medical examinations every two years, while occupational disease compensation mechanisms support medical care and rehabilitation.
Competitive LandscapeThe asbestosis treatment market competitive landscape is moderately fragmented, comprising respiratory medical device manufacturers, oxygen therapy providers, specialized healthcare institutions, and regional rehabilitation centers. Key players such as Inogen, CAIRE, Drive DeVilbiss Healthcare, Linde, AdaptHealth, and React Health are estimated to account for over 35% of the global asbestosis treatment market share.
Established companies compete through oxygen delivery technology, extensive distribution networks, and treatment accessibility. Regional providers in the asbestosis treatment market ecosystem focus on affordable respiratory support, specialized pulmonary rehabilitation, and personalized patient care.
List of Key and Emerging Players in Asbestosis Treatment Market-
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd.
Inogen, Inc.
CAIRE Inc.
Medical Depot, Inc. dba Drive DeVilbiss Healthcare
GCE Group
Belluscura Health
O2 Concepts, LLC
Fisher & Paykel Healthcare Corporation Limited
ResMed Inc.
September 2026: Inogen signed an agreement to sell its U.S. oxygen rental business to Rotech Healthcare for up to USD 25 million, alongside a long-term oxygen concentrator supply agreement.
August 2026: Inogen announced the launch of its Rove 6 portable oxygen concentrator in Canada, expanding access to oxygen therapy equipment for patients with chronic respiratory conditions.
July 2026: Philips received U.S. FDA 510(k) clearance for its next-generation reusable SpO2 clip sensor, designed to improve oxygen saturation measurement accuracy.
Report Scope| Market Metric | Details & Data (2025-2034) |
|---|---|
| Market Size in 2025 | USD 1.94 Billion |
| Market Size in 2026 | USD 2.05 Billion |
| Market Size in 2034 | USD 3.22 Billion |
| CAGR | 5.80% (2026-2034) |
| Base Year for Estimation | 2025 |
| Historical Data | 2022-2024 |
| Forecast Period | 2026-2034 |
| Study Period | 2025-2034 |
| Dominant Region | North America |
| Fastest Growing Region | Asia Pacific |
| Key Market Players | Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Inogen, Inc., CAIRE Inc., Medical Depot, Inc. dba Drive DeVilbiss Healthcare |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
| Segments Covered | By Treatment Type, By Disease Severity, By Age Group, By Healthcare Setting |
| Geographies Covered | North America, Europe, APAC, Middle East and Africa, LATAM |
| Countries Covered | US, Canada, UK, Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia |
Customize This Report to Match Your Strategic Objectives
Frequently Asked Questions (FAQs)
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment